| Autor: |
Naseef, Hani, Afaneh, Mosab, Qurt, Moammal, Rabba, Abdullah, Abukhalil, Abdallah, Malkieh, Numan, Kharouf, Maher, Moqadi, Ramzi |
| Zdroj: |
Talanta Open; August 2024, Vol. 9 Issue: 1 |
| Abstrakt: |
Rivaroxaban and aspirin are commonly used antithrombotic agents in combination to prevent coronary artery disease (CAD) and atherothrombotic events in adult patients after acute coronary syndrome (ACS) with elevated cardiac biomarkers, or with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) in high-risk patients. The recommended dosage is 2.5 mg rivaroxaban twice daily in combination with 75–100 mg aspirin once daily. This study aimed to develop a fixed-dose combination tablet of rivaroxaban (2.5 mg) and aspirin (50 mg) to enhance medication adherence and decrease pill burden. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
